More than 50 published clinical studies have been conducted on Chr. Hansen's BB-12 Bifidobacterium, LA-5 Lactobacillus acidophilus and L. casei 431.
More than 50 published clinical studies have been conducted on Chr. Hansen's BB-12 Bifidobacterium, LA-5 Lactobacillus acidophilus and L. casei 431. In studies evaluating these specific strains, researchers report enhanced intestinal well-being and positive effects on diarrhea, antibiotic-associated diarrhea, traveler's diarrhea and constipation, as well as enhanced immunity and positive effect on the skin disorder, atopic dermatitis. Proprietary encapsulation and tableting technology allows the probiotic bacteria to survive passage through the stomach and reach the small intestine. The company manufactures its probiotics using GMP and pharmaceutical standards.

All content and features on this website are copyrighted with all rights reserved. The full details can be found in our privacy statement
Upcoming webinars

Introducing LifeChews® and the Next Generation of Plant-based Supplements
Sirio
Register now

Why ARA & DHA matter: Key lipids shaping infant development
dsm-firmenich
Register now

Where Structure Drives Beauty: From Scalp Health to Skin Radiance
Monteloeder
Register now
All upcoming webinars
Subscribe to our newsletters
By continuing to browse our site you agree to our Privacy Statement










